/MAYNF

MAYNF Stock - Mayne Pharma Group Limited

Q: What is the analyst price target for MAYNF?

Analyst price target information is not currently available for MAYNF.

Q: What is MAYNF's market cap?

Market capitalization information is not currently available for MAYNF.

Healthcare|Drug Manufacturers - General|OTC

$2.36+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.60

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MAYNF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2021

FY2022

FY2023

FY2024

FY2025

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.14

52W High$4.60

52W Low$2.36

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$408.10M	$388.15M	$183.59M	$157.15M	$400.32M
Gross Profit	$247.27M	$218.53M	$26.84M	$170.15M	$194.74M
Gross Margin	60.6%	56.3%	14.6%	108.3%	48.6%
Operating Income	$-23,593,000	$-139,063,000	$-186,444,000	$-135,600,000	$-36,504,000
Net Income	$-93,836,000	$-174,233,000	$117.25M	$-209,481,000	$-208,423,000
Net Margin	-23.0%	-44.9%	63.9%	-133.3%	-52.1%
EPS	$-1.14	$-2.12	$-3.85	$-3.20	$-2.65

Company Overview

Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, New Zealand, the United States, Canada, Europe and Asia. The company operates through four segments: Metrics Contract Services, International, Branded Products, and Portfolio Products. It provides oral drug delivery systems; and contract pharmaceutical development, manufacturing, and analytical services to third-party customers, as well as distributes specialty pharmaceutical products in the dermatology, women's health, and infectious disease therapeutic areas. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.

Visit Website

Earnings History & Surprises

MAYNF

Beat Rate

Last 11 quarters

Avg Surprise

-625.9%

EPS vs Estimate

Beats / Misses

1/10

Last 12 quarters

Latest EPS

$-0.16

Q1 2025

EPS Surprise History

Q2 21

+30.0%

$-0.23vs$-0.33

Q4 21

-487.2%

$-0.45vs$-0.08

Q2 22

-1143.5%

$-1.66vs$-0.13

Q4 22

-103.2%

$-1.12vs$-0.55

Q2 23

-260.4%

$-1.37vs$-0.38

Q2 24

-88.8%

$-0.59vs$-0.31

Q3 24

-489.5%

$-0.88vs$-0.15

Q1 25

-102.4%

$-0.16vs$-0.08

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Feb 23, 2026	—	—	—	—
Q1 2025	Feb 24, 2025	$-0.08	$-0.16	-102.4%	✗ MISS
Q3 2024	Aug 22, 2024	$-0.15	$-0.88	-489.5%	✗ MISS
Q2 2024	May 13, 2024	$-0.31	$-0.59	-88.8%	✗ MISS
Q2 2023	Jun 30, 2023	$-0.38	$-1.37	-260.4%	✗ MISS
Q4 2022	Dec 30, 2022	$-0.55	$-1.12	-103.2%	✗ MISS
Q2 2022	Jun 30, 2022	$-0.13	$-1.66	-1143.5%	✗ MISS
Q4 2021	Dec 30, 2021	$-0.08	$-0.45	-487.2%	✗ MISS
Q2 2021	Jun 30, 2021	$-0.33	$-0.23	+30.0%	✓ BEAT
Q4 2020	Dec 30, 2020	$-0.05	$-1.78	-3178.4%	✗ MISS
Q2 2020	Jun 30, 2020	$-0.07	$-0.62	-832.8%	✗ MISS
Q4 2019	Dec 30, 2019	$-0.05	$-0.16	-228.8%	✗ MISS
Q2 2019	Jun 30, 2019	—	$-2.39	—	—
Q4 2018	Dec 31, 2018	—	$0.03	—	—
Q2 2018	Jun 30, 2018	—	$0.41	—	—
Q4 2017	Dec 31, 2017	—	$-1.83	—	—
Q2 2017	Jun 30, 2017	—	$0.16	—	—
Q4 2016	Dec 31, 2016	—	$0.75	—	—
Q2 2016	Jun 30, 2016	—	$0.33	—	—
Q4 2015	Dec 31, 2015	—	$0.35	—	—

Frequently Asked Questions about MAYNF

What is MAYNF's current stock price?

Mayne Pharma Group Limited (MAYNF) is currently trading at $2.36 per share. The stock has moved +0.00% today.

What is the analyst price target for MAYNF?

No analyst price targets are currently available for this stock.

What sector is Mayne Pharma Group Limited in?

Mayne Pharma Group Limited operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the OTC exchange.

What is MAYNF's market cap?

Mayne Pharma Group Limited has a market capitalization of $0.19 billion, making it a small-cap company.

Does MAYNF pay dividends?

No, Mayne Pharma Group Limited does not currently pay a dividend to shareholders.